KYMERA THERAPEUTICS, INC. Operating Cash Flow
KYMERA THERAPEUTICS, INC. (KYMR) reported Operating Cash Flow of -$142.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$54.06M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$88.84M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$66.75M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$27.11M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$232.89M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$194.50M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$102.83M.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$153.09M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$54.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$142.91M 10-Q · filed 2026-08-05 | -$209.65M derived: sum of 3 quarters · filed 2026-08-05 | -$236.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$88.84M 10-Q · filed 2026-04-30 | -$155.59M derived: sum of 2 quarters · filed 2026-04-30 | -$182.70M derived: sum of 3 quarters · filed 2026-04-30 | -$242.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$66.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$93.86M derived: sum of 2 quarters · filed 2026-02-26 | -$153.74M derived: sum of 3 quarters · filed 2026-08-05 | -$232.89M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$27.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$86.99M derived: sum of 2 quarters · filed 2026-08-05 | -$166.14M 10-Q · filed 2025-11-04 | -$227.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$59.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$139.03M 10-Q · filed 2026-08-05 | -$200.82M derived: sum of 3 quarters · filed 2026-08-05 | -$251.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$79.15M 10-Q · filed 2026-04-30 | -$140.93M derived: sum of 2 quarters · filed 2026-04-30 | -$191.12M derived: sum of 3 quarters · filed 2026-04-30 | -$234.06M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$61.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$111.97M derived: sum of 2 quarters · filed 2026-02-26 | -$154.91M derived: sum of 3 quarters · filed 2026-02-26 | -$194.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$50.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$93.13M derived: sum of 2 quarters · filed 2025-11-04 | -$132.72M 10-Q · filed 2025-11-04 | -$124.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$42.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$82.53M 10-Q · filed 2025-08-11 | -$74.48M derived: sum of 3 quarters · filed 2026-02-26 | -$106.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$39.59M 10-Q · filed 2025-05-09 | -$31.55M derived: sum of 2 quarters · filed 2026-02-26 | -$63.19M derived: sum of 3 quarters · filed 2026-02-26 | -$98.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$23.60M derived: sum of 2 quarters · filed 2026-02-26 | -$58.86M derived: sum of 3 quarters · filed 2026-02-26 | -$102.83M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$31.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$66.90M derived: sum of 2 quarters · filed 2024-10-31 | -$110.87M 10-Q · filed 2024-10-31 | -$150.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$35.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$79.22M 10-Q · filed 2024-08-07 | -$118.76M derived: sum of 3 quarters · filed 2025-02-27 | -$153.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$43.97M 10-Q · filed 2024-05-02 | -$83.50M derived: sum of 2 quarters · filed 2025-02-27 | -$117.77M derived: sum of 3 quarters · filed 2025-02-27 | -$156.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$39.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$73.81M derived: sum of 2 quarters · filed 2025-02-27 | -$112.79M derived: sum of 3 quarters · filed 2025-02-27 | -$153.09M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$34.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$73.25M derived: sum of 2 quarters · filed 2023-11-02 | -$113.55M 10-Q · filed 2023-11-02 | -$151.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$38.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$79.28M 10-Q · filed 2023-08-03 | -$117.63M derived: sum of 3 quarters · filed 2024-02-22 | -$154.89M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$40.30M 10-Q · filed 2023-05-04 | -$78.65M derived: sum of 2 quarters · filed 2024-02-22 | -$115.91M derived: sum of 3 quarters · filed 2024-02-22 | -$146.42M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$38.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$75.61M derived: sum of 2 quarters · filed 2024-02-22 | -$106.12M derived: sum of 3 quarters · filed 2024-02-22 | -$128.95M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$37.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$67.77M derived: sum of 2 quarters · filed 2022-11-03 | -$90.59M 10-Q · filed 2022-11-03 | -$110.66M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$30.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$53.33M 10-Q · filed 2022-08-09 | -$73.40M derived: sum of 3 quarters · filed 2023-02-23 | $58.27M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$22.82M 10-Q · filed 2022-05-03 | -$42.89M derived: sum of 2 quarters · filed 2023-02-23 | $88.78M derived: sum of 3 quarters · filed 2023-02-23 | $77.36M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$20.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $111.60M derived: sum of 2 quarters · filed 2023-02-23 | $100.19M derived: sum of 3 quarters · filed 2023-02-23 | $88.13M 10-K · filed 2023-02-23 |
| 2020-09-30 | $131.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $120.25M derived: sum of 2 quarters · filed 2021-11-10 | $108.20M 10-Q · filed 2021-11-10 | $97.40M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$11.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$23.47M 10-Q · filed 2021-08-06 | -$34.27M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$12.06M 10-Q · filed 2021-05-06 | -$22.86M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $17.91M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $28.71M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |